It is uncertain how body mass index impacts cardiovascular outcomes among patients receiving intensive low-density lipoprotein cholesterol–lowering therapy. New research has shed light on the association.
...
The FDA has approved a new agent for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established ASCVD as an adjunct to diet and maximally tolerated statin therapy.
Technologies discussed in the section include insulin pens and pumps, meters and monitors for blood glucose levels, and devices that both measure glucose and deliver insulin.
Because management of LDL-C is critical for treating atherosclerotic cardiovascular disease, authors of a new study evaluated the utilization of pharmacotherapy among more than 280,000 individuals with the...
As both the prevalence of obesity and the number of MS cases increases, researchers say it is important to examine the relationship between obesity in children and adolescents and the later occurrence of...
As both the prevalence of obesity and the number of MS cases increases, researchers say it is important to examine the relationship between obesity in children and adolescents and the later occurrence of...
Hypertension guidelines recommend limits for systolic and diastolic blood pressure. But regardless of whether systolic BP is controlled, diastolic BP can still affect cardiovascular outcomes.
To evaluate the safety of the test, researchers assessed patients presenting with chest pain and other symptoms of a heart attack at an emergency room in Texas.
Previous evidence has linked high levels of HDL cholesterol to lower risk of heart disease, but recent studies have begun to question how good the “good” cholesterol actually is.
